PHIO experienced a dramatic improvement in financial position with stockholders' equity surging 327% to $20.1M and cash increasing 291% to $21.0M, likely from equity financing, though operating losses deepened to $9.2M.
The massive increase in cash and equity suggests PHIO completed a significant capital raise, providing substantial runway for operations and clinical trials. However, the 25% increase in operating losses to $9.2M indicates accelerating cash burn that could offset the benefits of the new capital if not managed effectively.
PHIO's balance sheet was dramatically strengthened with stockholders' equity jumping 327% to $20.1M and cash surging 291% to $21.0M, while current liabilities decreased 38%, indicating a major capital infusion likely through equity financing. However, the income statement deteriorated with R&D expenses rising 27% to $4.6M and operating losses widening 25% to $9.2M, reflecting increased clinical trial activity and operational costs. The overall picture shows a biotech company that has secured significant funding but is experiencing accelerating cash burn as it advances its pipeline.
Capital expenditure jumped 1100% — major investment cycle underway; assess returns on deployment.
Equity base grew 326.6% — retained earnings accumulation or equity issuance strengthening the balance sheet.
Cash position surged 290.8% — strong cash generation or capital raise providing significant financial cushion.
Asset base grew 274.5% — expansion through organic growth, acquisitions, or capital deployment.
Current assets grew 274.4% — improving short-term liquidity or inventory/receivables build.
Current liabilities reduced — improved short-term financial position and working capital health.
Liabilities grew 32% — significant increase in debt or obligations, assess impact on financial flexibility.
R&D investment increased 26.8% — signals commitment to future product development, though near-term margin impact.
Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.
Net income declined 21.7% — review whether driven by operations, interest costs, or non-recurring items.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →